Found 412 hits.
| 167. | Maltseva, N., Borzova, E., Fomina, D., Bizjak, M., Terhorst-Molawi, D., Košnik, M., Kulthanan, K., Meshkova, R., Thomsen, S. F., and Maurer, M.+: Cold urticaria – what we know and what we do not know. Allergy 2021: in press. IF: 14.71 |
r.167
| 96 | Zuberbier, T.+, Balke, M., Worm, M., Edenharter, G., and Maurer, M.: Epidemiology of urticaria: a representative cross-sectional population survey. Clin. Exp. Dermatol. 2010: 35; 869-873. IF: 1.26 |
| 69. | Valent, P., Arock, M., Bonadonna, P., Brockow, K., Broesby-Olsen, S., Escribano, L., von Gleixner, K., Grattan, C., Hadzijusufovic, E., Hägglund, H., Hermine, O., Horny, H. P., Kluin-Nelemans, H. C., Maurer, M., Niedoszytko, M., Nedoszyotko, B., Nilsson, G., Oude Elberink, H. N. G., Orfao, Radia, D., A., Reiter, A., Siebenhaar, F., Sotlar, K., Sperr, W. R., Triggiani, M., VanDormaal, J. J., Várkonyi, J., Yavuz, S., and Hartmann, K.: European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien. Klin. Wochenschr. 2012: 124; 807-814. IF: 0.81 |
| 404. | Riedl, M. A.+, Maurer, M., Bernstein, J. A., Banerji, A., Longhurst, H. J., Henry Li, H., Lu, P., Hao, J., Juethner, S., and Lumry, W. R.: Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks. Allergy 2020: 75; 2879-2887. IF: 13.15 |
o.404
| 414. | Kolkhir, P., Altrichter, S., Asero, R., Daschner, A., Ferrer, M., Giménez-Arnau, A., Hawro, T., Jakob, T., Kinaciyan, T., Kromminga, A., Konstantinou, G. N. Makris, M., Metz, M., Stahl Skov, P., Staubach, P., Sussman, G., Zhang, K., and Maurer, M.+: Autoimmune diseases are linked to type IIb autoimmune chronic spontaneous urticaria. Allergy Asthma Immunol. Res. 2021: 13; 545-559. IF: 5.10 |
o.414
| 388. | Weller, K.+, Donoso, T., Magerl, M., Aygören-Pürsün, E., Staubach, P., Martinez-Saguer, I., Hawro, T., Altrichter, S., Krause, K., Siebenhaar, F., Metz, M., Zuberbier, T., Freier, D., and Maurer, M.: Validation of the angioedema control test (AECT) – a patient reported outcome instrument for assessing angioedema control. J. Allergy Clin. Immunol. Pract. 2020: 8; 2050-2057. IF: 8.86 |
o.388
| 233 | Kulthanan, K., Chularojanamontri, L.+, Tuchinda, P., Rujitharanawong, C., Maurer, M. and Weller, K.: Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). Health Qual. Life Outcomes 2016: 14; 61-70. IF: 2.14 |
| 91 | Młynek, A., Magerl, M., Siebenhaar, F., Weller, K., Vieira dos Santos, R., Zuberbier, T., Zalewska-Janowska, A., and Maurer, M.+: Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Brit. J. Dermatol. 2010: 162; 198-200. IF: 4.35 |
| 269 | Metz, M., Staubach, P., Bauer, A., Brehler, R., Gericke, J., Kangas, M., Ashton-Chess, J., Jarvis, P., Georgiou, P., Canvin, J., Hillenbrand, R., Erpenbeck, V. J., and Maurer, M.+: Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcɛRI-positive cells in the skin. Theranostics 2017: 7; 1266-1276. IF: 8.54 |
| 326 | Riedl, M.*+, Farkas, H.*, Bernstein, J. A., Bouillet, L., Sheridan, W. P., and Maurer, M.: Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPuS-2 study. Allergy 2018: 73; 1871-1880. IF: 6.77 |